廖 信閔

Medicine & Life Sciences

1. Chronic Obstructive Pulmonary Disease 100%
2. Cohort Studies 32%
3. Asthma 31%
4. angiotensin converting enzyme 2 23%
5. Fenoterol 23%
6. Pulmonary Aspergillosis 23%
7. Coronavirus Infections 23%
8. Mortality 22%
9. Population 21%
10. Bronchial Spasm 20%
11. Severe Acute Respiratory Syndrome 20%
12. Bronchoscopy 19%
13. Bronchodilator Agents 18%
14. Alveolar Macrophages 17%
15. Sleep Apnea Syndromes 17%
16. Life Expectancy 15%
17. Mood Disorders 15%
18. Omalizumab 15%
19. Tobacco Products 15%
20. Human Influenza 14%
21. Antipsychotic Agents 14%
22. Atrial Fibrillation 14%
23. Reactive Oxygen Species 12%
24. Quality of Life 12%
25. Epithelium 12%
26. Logistic Models 11%
27. Palliative Care 10%
28. prednylidene 9%
29. Bronchoalveolar Lavage 9%
30. Calcium Channel Blockers 8%
31. Biological Products 7%
32. Proportional Hazards Models 7%
33. Hospitalization 7%
34. Area Under Curve 7%
35. Enzymes 7%
36. Least-Squares Analysis 6%
37. Aspergillus 6%
38. Biological Factors 5%
39. Coronavirus 5%
40. Sympathomimetics 5%